US Cancer Vaccine Market Research Report forecast 2022
Summary - A new
market study, titled “US Cancer Vaccine Market Outlook 2022” has been
featured on Wise Guy Reports.
Cancer is
one of the major health issues faced by the countries across the globe. The
researchers are engaged in developing various drugs for the prevention and
treatment of the disease. Cancer vaccine is one such example. Since their
inception, cancer vaccines were considered as high potential method for
preventing and treating cancer. Till date, the vaccines have not been able to
achieve the expected sales due to high cost and negative results in clinical
trials. However, with launch of new cancer vaccines, such as Imlygic by Amgen;
and increasing awareness of people regarding these vaccines, the market is
expected to grow.
The US is
largest market for cancer vaccines. The growth of the US cancer vaccine market
is driven by increasing cancer incidence in the country, rising awareness, and
strong pipeline. The “US Cancer Vaccine Market Outlook 2022” report provides
detailed analysis of the market. This report covers the present scenario and
the growth prospects of US cancer vaccine market for the period 2015-2022. It
also covers the drivers, restraints hampering the growth of the market, and
future opportunities. Moreover, the report provides the global sales of various
cancer vaccines from 2013-2015.
On the basis
of type of cancer for which the vaccine is targeted, the market has been
segmented into three types, namely, liver cancer, HPV related cancer, and
others. Currently, HPV related cancer vaccines occupy the largest share in the
US market.
On the basis of type of vaccine, the market has
been further sub-divided into prophylactic vaccines and therapeutic vaccines.
The prophylactic vaccines accounts for the largest share in 2016. The large share
of this market is attributed to various vaccination programs organized by the
US government for prevention against HPV and hepatitis. The therapeutic
vaccines are expected to witness high growth in coming years due to strong
pipeline. Amongst the various research studies, a vaccine for lung cancer can
be expected to come up soon with promising candidates, such as TV4010 and
GV1001, having entered phase 3 trials.
The report also provides market share analysis by
key players. Merck and GSK are expected to continue to be undisputed market
leaders in the cancer vaccine market. Furthermore, the report also covers the
FDA's vaccine approval procedure, and its guidance to the industry for
developing therapeutic cancer vaccines. Additionally, the report also enlists
the pipeline of cancer vaccines which are in various clinical trial phases. The
patent analysis of products in US has also been added in the report on the
basis of year of grant, type of patent, and assignee of the patent.
The last section of the report discusses about
the key players in the US cancer vaccine market. A brief business overview and
financial information about each of these players has been provided in the
report. Moreover, this report will help the reader to gain crucial insight into
the key players’ performances and strategies for growth. Conclusively, the
research will prove to be a useful resource for all debut makers in US cancer
vaccine industry and potential investors.
REPORT DETAILS : https://www.wiseguyreports.com/reports/1706451-us-cancer-vaccine-market-outlook-2022
About Us :
Wise Guy
Reports is part of the Wise Guy Research Consultants Pvt. Ltd. And offers
premium progressive statistical surveying, market research reports, analysis
& forecast data for industries and governments around the globe.
Contact Us:
NORAH
TRENT
Ph:
+162-825-80070
(US)
Ph: +44 203
500 2763 (UK)
Comments
Post a Comment